Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing ...

Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

Revolutionizing Alzheimer's care, Zunveyl minimizes GI and sleep side effects. Discover its market potential and why it's ...

Department of Chemistry, Faculty of Education, Gifu University, Gifu 501-1193, Japan, Molecular Graphics and Computational Facility, College of Chemistry, University of California, Berkeley, ...

The molecular mechanism of cytokine regulation by the inflammatory reflex depends on signal transduction by the nicotinic acetylcholine receptor α7 subunit (α7nAChR). Administration of selective ...

The subtype-selective binding of 14 representative agonists with α4β2 and α7 nicotinic acetylcholine receptors (nAChRs) has been studied by performing homology modeling, molecular docking, geometry ...

The molecular mechanisms of nicotinic receptor activation are ... single H‐bond between two different acetylcholine binding loops. Within these homologous loops we systematically introduced α4 ...

plays an anti-inflammatory role during inflammation by acting on the α7 nicotinic acetylcholine receptor(α7nAchR) to promote the secretion of anti-inflammatory factors. However, the specific role of ...

MaGic is a global, randomized, double-blind, placebo-controlled phase 2 trial that enrolled 65 patients with acetylcholine receptor (AChR) antibody positive gMG, exceeding the enrollment target of 60 ...

The Food and Drug Administration (FDA) has approved Imaavy ™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...